529 related articles for article (PubMed ID: 22281991)
41. Effect of iron overload on endocrinopathies in patients with beta-thalassaemia major and intermedia.
Kurtoglu AU; Kurtoglu E; Temizkan AK
Endokrynol Pol; 2012; 63(4):260-3. PubMed ID: 22933160
[TBL] [Abstract][Full Text] [Related]
42. Desferrioxamine induced urinary iron excretion in thalassemia.
Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
[TBL] [Abstract][Full Text] [Related]
43. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
[TBL] [Abstract][Full Text] [Related]
44. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
[TBL] [Abstract][Full Text] [Related]
45. Intensification of chelating-therapy in patients with thalassemia major.
Laws HJ; Göbel U; Christaras A; Janssen G
Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
[TBL] [Abstract][Full Text] [Related]
46. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
[TBL] [Abstract][Full Text] [Related]
47. Complications of beta-thalassemia major in North America.
Cunningham MJ; Macklin EA; Neufeld EJ; Cohen AR;
Blood; 2004 Jul; 104(1):34-9. PubMed ID: 14988152
[TBL] [Abstract][Full Text] [Related]
48. Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center.
Gamberini MR; Fortini M; De Sanctis V; Gilli G; Testa MR
Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():285-91. PubMed ID: 16462713
[TBL] [Abstract][Full Text] [Related]
49. Study of serum hepcidin in hereditary hemolytic anemias.
El Beshlawy A; Alaraby I; Abdel Kader MS; Ahmed DH; Abdelrahman HE
Hemoglobin; 2012; 36(6):555-70. PubMed ID: 23088733
[TBL] [Abstract][Full Text] [Related]
50. [Liver and heart iron deposition status in patients with β thalassemia major: a multicenter study].
Li C; Liu S; Wang Y; Wen F; Gao H; Chen G; Li C; Wu X; Fang J; Hao W; Liu R; Zhang X; Chu CW; Au W
Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):90-3. PubMed ID: 24739717
[TBL] [Abstract][Full Text] [Related]
51. Serum ferritin concentrations in transfusion dependent beta-thalassaemia.
George E; Wong HB; George R; Ariffin WA
Singapore Med J; 1994 Feb; 35(1):62-4. PubMed ID: 8009283
[TBL] [Abstract][Full Text] [Related]
52. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores.
Tony S; Daar S; Elshinawy M; Al-Zadjaly S; Al-Khabori M; Wali Y
Pediatr Hematol Oncol; 2012 Sep; 29(6):579-84. PubMed ID: 22839111
[TBL] [Abstract][Full Text] [Related]
53. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
[TBL] [Abstract][Full Text] [Related]
54. Pituitary iron and volume predict hypogonadism in transfusional iron overload.
Noetzli LJ; Panigrahy A; Mittelman SD; Hyderi A; Dongelyan A; Coates TD; Wood JC
Am J Hematol; 2012 Feb; 87(2):167-71. PubMed ID: 22213195
[TBL] [Abstract][Full Text] [Related]
55. Compliance with Deferoxamine Therapy and Thyroid Dysfunction of Patients with β-Thalassemia Major in Syria.
Yassouf MY; Alquobaili F; Kabalan Y; Mukhalalaty Y
Hemoglobin; 2019 May; 43(3):218-221. PubMed ID: 31373517
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
[TBL] [Abstract][Full Text] [Related]
57. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients.
Fraquelli M; Cassinerio E; Roghi A; Rigamonti C; Casazza G; Colombo M; Massironi S; Conte D; Cappellini MD
Am J Hematol; 2010 Aug; 85(8):564-8. PubMed ID: 20658587
[TBL] [Abstract][Full Text] [Related]
58. The spectrum of ocular alterations in patients with β-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum.
Barteselli G; Dell'arti L; Finger RP; Charbel Issa P; Marcon A; Vezzola D; Mapelli C; Cassinerio E; Cappellini MD; Ratiglia R; Viola F
Ophthalmology; 2014 Mar; 121(3):709-18. PubMed ID: 24314836
[TBL] [Abstract][Full Text] [Related]
59. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
[TBL] [Abstract][Full Text] [Related]
60. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
